Management of Stable Vitiligo
Conditions
Brief summary
For each patient, one side of body will be treated with NB-UVB alone while the other side will be treated with NB-UVB therapy in addition to intradermal injection of PRP every 2 weeks. Patients will be photographed at the first visit, in the middle and at the end of therapy. Each patient will sign a written consent form to be included in the study and to be photographed.
Interventions
PROCEDUREplatelet rich plasma, narrow band UVB
Role of PRP in treating stable vitiligo
Sponsors
Sohag University
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
15 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
Patients with stable non segmental vitiligo. (Absence of koebnerization, absence of new lesion and absence of widening of the existing lesions). Patients have more than 15 years. \-
Exclusion criteria
Patients have active vitiligo (appearance of new lesion, history of koebnerization). Pregnant and lactating women. History of keloid formation. Anemia (hemoglobin level \<10gm/dl), thrombocytopenia (platelet count \<100,000 /µL), coagulopathies or patients on anticoagulant therapy and patients with iron deficiency. Patients taking drugs that prolong bleeding time such as Aspirin and vitamin E Patients taking treatment of vitiligo in last 2 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement of vitiligo | within 6 months | increase repigmentation score |
Countries
Egypt
Outcome results
None listed